Daily Cardiology Research Analysis
Three impactful cardiology studies stood out today: a large population-based analysis challenged routine epinephrine use for refractory shockable cardiac arrest; a Danish nationwide cohort quantified specific cardiovascular risks among cancer survivors after systemic therapy; and a network meta-analysis identified cardiac MRI regurgitant indices that best predict outcomes in asymptomatic moderate-to-severe aortic regurgitation.
Summary
Three impactful cardiology studies stood out today: a large population-based analysis challenged routine epinephrine use for refractory shockable cardiac arrest; a Danish nationwide cohort quantified specific cardiovascular risks among cancer survivors after systemic therapy; and a network meta-analysis identified cardiac MRI regurgitant indices that best predict outcomes in asymptomatic moderate-to-severe aortic regurgitation.
Research Themes
- Resuscitation pharmacology and outcomes in refractory ventricular fibrillation
- Cardio-oncology: long-term cardiovascular risk after systemic cancer therapy
- Imaging-based prognostication in valvular heart disease (aortic regurgitation)
Selected Articles
1. Association of epinephrine and outcome in cardiac arrest with refractory shockable rhythm: a population-based, propensity-score matched analysis.
In a prospective population-based registry of 3,163 patients with refractory ventricular fibrillation after ≥3 shocks, epinephrine use (81%) was associated with markedly lower favorable neurological survival (11% vs 50%) and remained negatively associated after multivariable and multiple propensity-based analyses. The findings challenge routine epinephrine administration in refractory shockable rhythms.
Impact: This large, methodologically robust registry consistently links epinephrine with worse neurological outcomes in a high-risk, guideline-relevant subgroup, potentially prompting reappraisal of resuscitation algorithms.
Clinical Implications: For refractory shockable rhythms, prioritize rapid, high-quality defibrillation and consider minimizing or delaying epinephrine while evaluating alternative strategies (e.g., early ECPR access, antiarrhythmics) within systems of care and clinical trials.
Key Findings
- Among 3,163 refractory VF cases, epinephrine was administered in 81% but associated with lower favorable neurological survival (11% vs 50%).
- Adjusted analyses showed epinephrine independently associated with worse outcomes (aOR ~0.24) across multivariable, propensity-adjusted, matched, and IPW analyses.
- Results were robust in sensitivity analyses, challenging systematic epinephrine use in refractory shockable arrest.
Methodological Strengths
- Prospective, population-based registry across a large regional system
- Multiple analytic strategies (multivariable, propensity adjustment/matching, IPW) with consistent findings
Limitations
- Observational design with potential residual confounding and confounding by indication
- Timing/dose of epinephrine and time-dependent biases may influence associations
Future Directions: Randomized or pragmatic trials targeting refractory shockable rhythms should test epinephrine-sparing protocols versus standard care and evaluate alternative pharmacologic and ECPR-based strategies.
BACKGROUND: Epinephrine use in cardiac arrest is increasingly controversial, with contrasting results according to initial rhythm. We assessed the association between epinephrine use and favorable neurological outcome among patients with out of hospital cardiac arrest with refractory shockable arrest. METHODS: In this multicentric population-based prospective registry, we included all patients with out-of-hospital cardiac arrest, with persistent ventricular fibrillation after at least 3 defibrillations from 15/05/2011 to 31/12/2021 in Paris and its suburbs. Primary outcome was survival with a favorable neurological outcome (Cerebral Performance Categories level 1 or 2 at hospital discharge). A multivariate logistic regression analysis and a propensity score analysis with adjustment, matching and inverse probability weighting were performed. RESULTS: Among the 3163 patients with refractory shockable arrest, 2572 (81%) received epinephrine. Primary outcome was achieved in 270 patients (11%) among those who received epinephrine, and in 294 patients (50%) among those who did not. After adjustment, epinephrine use remained negatively associated with favorable outcome (aOR 0.24, 95%CI 0.19-0.31, p < 0.001). This negative association between epinephrine and favorable outcome was consistent after adjustement for propensity-score (aOR 0.24, 95%CI 0.18-0.31, p < 0.001), matching on propensity score (aOR 0.40, 95%CI 0.31-0.51, p < 0.001), and in various sensitivity analyses. CONCLUSION: In a large population-based registry of patients experiencing refractory ventricular fibrillation, epinephrine use was consistently associated with worse outcome using various methodological approaches. These findings are challenging the systematic use of epinephrine in refractory ventricular fibrillation.The use of potential alternative therapeutic strategies might be evaluated in this population.
2. Risk of Cardiovascular Disease in Cancer Survivors after Systemic Treatment: A Population-Based Cohort Study.
In a nationwide matched cohort (91,407 survivors; 457,035 controls), cancer survivors formerly treated with systemic therapy had increased risks of heart failure/cardiomyopathy (HR 1.08), venous thromboembolism (HR 1.50), inflammatory cardiac diseases (HR 1.30), and kidney failure (HR 1.17) over up to 5 years. Risks varied by cancer type and agents (e.g., stroke signal with platinum compounds).
Impact: Provides granular, population-level estimates of post-therapy cardiovascular risks, enabling targeted cardio-oncology surveillance and prevention.
Clinical Implications: Implement risk-tailored surveillance for heart failure/cardiomyopathy, VTE, and inflammatory cardiac conditions in cancer survivors, with attention to agent-specific risks (e.g., platinum-associated stroke).
Key Findings
- Cancer survivors (n=91,407) had higher risks vs matched controls for HF/cardiomyopathy (HR 1.08), VTE (HR 1.50), inflammatory cardiac disease (HR 1.30), and kidney failure (HR 1.17).
- No overall increase in ischemic heart disease, stroke, or atrial fibrillation; however, stroke was associated with platinum compounds, and ischemic heart disease increased in lung cancer survivors.
- Risk heterogeneity by cancer type and treatment underscores need for personalized survivorship care.
Methodological Strengths
- Nationwide, population-based matched cohort with large sample size and up to 5-year follow-up
- Adjusted Cox models accounting for key confounders; agent- and cancer-specific analyses
Limitations
- Observational design; potential residual confounding and misclassification from registry-based data
- Lack of granular dosing/exposure data and cardiac imaging endophenotypes
Future Directions: Integrate treatment exposure metrics and biomarkers/imaging to refine individualized cardio-oncology risk models and evaluate preventive interventions.
BACKGROUND: Patients face an increased risk of cardiovascular disease shortly after a cancer diagnosis, but evidence on long-term risk among cancer survivors remains limited. OBJECTIVES: In this study the authors sought to estimate the risk of cardiovascular disease in cancer survivors previously treated with systemic cancer therapy. METHODS: Using Danish population-based registries, we identified individuals who had received systemic cancer treatment and were free of both cancer and treatment 3 years after diagnosis (index date). For each cancer survivor, 5 cancer-free individuals from the general population were randomly selected, matched by birth year, sex, and calendar year. Participants were followed from the index date for up to 5 years. HRs were estimated using Cox regression, adjusted for potential confounders. RESULTS: Compared with 457,035 matched individuals, the 91,407 cancer survivors had an increased risk of heart failure or cardiomyopathy (HR: 1.08; 95% CI: 1.02-1.15), venous thromboembolism (HR: 1.50; 95% CI: 1.41-1.61), pericarditis, endocarditis, or myocarditis (HR: 1.30; 95% CI: 1.11-1.52), and kidney failure (HR: 1.17; 95% CI: 1.10-1.25), but not of ischemic heart disease, stroke, or atrial fibrillation. Estimates varied substantially by cancer type and treatment agent. For example, venous thromboembolism risk was consistently increased across nearly all cancer types, whereas hypertension risk was elevated for none. Ischemic heart disease risk was increased only among lung cancer survivors. Stroke was associated with platinum compounds but not with other systemic treatments. CONCLUSIONS: Several cardiovascular disease risks were elevated among cancer survivors, with substantial variation by cancer type and treatment.
3. Prognostic Value of Cardiovascular MRI in Asymptomatic Patients with Moderate-to-Severe Aortic Regurgitation: A Network Meta-Analysis.
Across 1,579 asymptomatic moderate-to-severe AR patients, CMR-derived regurgitant volume and fraction independently predicted adverse outcomes, with risk increasing per-unit increment. Markers of adverse LV remodeling (higher EDV/ESV) also tracked risk, supporting quantitative CMR for surveillance and timing of intervention.
Impact: Synthesizes multi-study evidence to prioritize CMR regurgitant indices and remodeling metrics for risk stratification in AR, informing surveillance thresholds beyond echocardiography alone.
Clinical Implications: In asymptomatic moderate-to-severe AR, consider integrating quantitative CMR (regurgitant volume/fraction and LV volumes) to refine timing for aortic valve intervention and intensify follow-up.
Key Findings
- CMR regurgitant volume (per 1 mL increase) and regurgitant fraction (per 1% increase) were significantly associated with adverse outcomes.
- Indices of adverse LV remodeling (higher EDV/ESV) tracked increased risk in network meta-analysis.
- Evidence supports a role for quantitative CMR in surveillance of asymptomatic moderate-to-severe AR.
Methodological Strengths
- Systematic review with both pairwise and network meta-analysis approaches
- Quantitative synthesis across multiple CMR parameters and outcomes
Limitations
- Heterogeneity in CMR protocols, thresholds, and outcome definitions across included studies
- Predominantly observational source studies; limited patient-level data
Future Directions: Prospective studies defining CMR-based intervention thresholds and integrating CMR with echocardiographic indices to guide timing of aortic valve replacement.
Purpose To determine the prognostic significance of cardiac MRI parameters in patients with moderate-to-severe aortic regurgitation (AR) and minimal or no symptoms through a network meta-analysis. Materials and Methods This systematic review and network meta-analysis searched in PubMed, Embase, and Cochrane Library databases for articles published from January 1, 2000, to March 1, 2024, investigating the prognostic value of cardiac MRI parameters in patients with moderate-to-severe AR. The composite outcome included all-cause death, heart failure hospitalization, aortic valve replacement, new-onset heart failure symptoms, New York Heart Association class progression, and left ventricular ejection fraction less than 50%. Both pairwise and network meta-analyses were performed. Results Eight studies with 1579 patients (1187 male patients [75%]; mean age, 55 years ± 5 [SD]) were included. Aortic regurgitant volume and regurgitant fraction were associated with a higher incidence of adverse events (pooled hazard ratio [HR], 1.04 per 1 mL increase [95% CI: 1.01, 1.06] and pooled HR, 1.09 per 1% increase [95% CI: 1.03, 1.16], respectively). Adverse remodeling, reflected by increased end-diastolic or end-systolic volume (pooled HR, 1.02 per 1 mL/m